Toronto Dominion Bank Acquires 5,474 Shares of Insulet Co. (NASDAQ:PODD)

Posted by on May 8th, 2023

Toronto Dominion Bank lifted its holdings in Insulet Co. (NASDAQ:PODD – Get Rating) by 37.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,122 shares of the medical instruments supplier’s stock after buying an additional 5,474 shares during the period. Toronto Dominion Bank’s holdings in Insulet were worth $5,920,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in PODD. Duality Advisers LP purchased a new position in shares of Insulet during the 4th quarter worth about $280,000. Bleakley Financial Group LLC purchased a new position in shares of Insulet during the 4th quarter worth about $253,000. Metis Global Partners LLC purchased a new position in shares of Insulet during the 4th quarter worth about $511,000. LPL Financial LLC boosted its stake in shares of Insulet by 6.3% during the 4th quarter. LPL Financial LLC now owns 17,213 shares of the medical instruments supplier’s stock worth $5,067,000 after purchasing an additional 1,025 shares during the period. Finally, FourThought Financial Partners LLC purchased a new position in shares of Insulet during the 4th quarter worth about $723,000.

Insider Buying and Selling at Insulet

In other Insulet news, insider Charles Alpuche sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 28th. The shares were sold at an average price of $278.82, for a total transaction of $1,115,280.00. Following the transaction, the insider now owns 45,584 shares in the company, valued at approximately $12,709,730.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Wayde D. Mcmillan sold 1,255 shares of the stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $318.31, for a total transaction of $399,479.05. Following the sale, the chief financial officer now directly owns 22,865 shares of the company’s stock, valued at $7,278,158.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Charles Alpuche sold 4,000 shares of the stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $278.82, for a total transaction of $1,115,280.00. Following the sale, the insider now directly owns 45,584 shares in the company, valued at $12,709,730.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,656 shares of company stock worth $9,819,174. 0.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PODD. Piper Sandler lifted their price target on shares of Insulet from $340.00 to $360.00 in a research note on Friday. UBS Group boosted their price objective on shares of Insulet from $328.00 to $360.00 in a research report on Friday. Barclays boosted their price objective on shares of Insulet from $245.00 to $292.00 in a research report on Friday, February 24th. Morgan Stanley boosted their price objective on shares of Insulet from $320.00 to $325.00 and gave the company an “equal weight” rating in a research report on Friday, February 24th. Finally, Robert W. Baird boosted their price objective on shares of Insulet from $350.00 to $370.00 in a research report on Friday. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $326.92.

Insulet Trading Up 2.0 %

NASDAQ PODD opened at $328.76 on Monday. The company has a quick ratio of 2.65, a current ratio of 3.60 and a debt-to-equity ratio of 2.88. The firm has a market cap of $22.91 billion, a PE ratio of 280.99 and a beta of 0.80. The company has a 50 day moving average price of $310.33 and a 200 day moving average price of $297.08. Insulet Co. has a 52 week low of $181.00 and a 52 week high of $335.91.

Insulet (NASDAQ:PODD – Get Rating) last posted its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported $0.23 EPS for the quarter, topping the consensus estimate of $0.09 by $0.14. Insulet had a net margin of 0.04% and a return on equity of 17.89%. The firm had revenue of $358.10 million during the quarter, compared to analyst estimates of $330.21 million. During the same quarter in the previous year, the business posted $0.40 EPS. Insulet’s revenue was up 21.2% on a year-over-year basis. As a group, sell-side analysts forecast that Insulet Co. will post 1.31 EPS for the current fiscal year.

Insulet Profile

(Get Rating)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.

Featured Stories

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD – Get Rating).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.